Compliance in Cell and Gene Therapy Manufacturing: Anticipating Global Trends

Cell and gene therapies (CGTs) and advanced therapy medicinal products (ATMPs) are transforming treatments for rare diseases and oncology. Their highly personalized nature offers extraordinary potential for patients but creates unique challenges for manufacturers tasked with ensuring consistent quality, scalability, and compliance with evolving regulatory expectations. The accelerating pace of CGT/ATMP development and manufacturing challenges are drawing heightened regulatory focus and compliance risk.

In mid-2025, FDA held its inaugural Cell & Gene Therapy Roundtable, signaling a willingness to modernize oversight and reduce procedural friction for breakthrough modalities. FDA also issued a trio of new draft guidances on regenerative medicine and CGT development, each with CMC and GMP compliance implications.

Simultaneously, regulators in Europe are preparing to modernize the GMP requirements. In 2025 the EMA adopted a multidisciplinary guideline for investigational ATMPs (quality, non-clinical, clinical) and published a concept paper to align ATMP-specific GMP (Part IV) with the 2023 Annex 1 revisions, explicitly encouraging risk-based controls tailored to complex modalities. While regulators in the U.S. and Europe are accelerating approval pathways to bring these therapies to patients faster, recent inspectional data reveal a parallel trend - an increase in enforcement actions tied to GMP deficiencies in this rapidly evolving space.

Over the past 3 years, there’s been a growing trend in the number of inspections of CGT-manufacturing facilities. FDA 483 observations and EMA inspection reports have highlighted recurring gaps across aseptic manufacturing, environmental monitoring, process validation, data governance, and supply chain management. These findings illustrate a critical tension in the field: as innovation accelerates, quality systems are often struggling to keep pace. The consequence is an elevated compliance risk profile that can delay approvals and limit patient access to life-changing therapies.

This session will explore how pharmaceutical scientists, quality professionals, and regulatory leaders can anticipate and adapt to this evolving global compliance landscape. Leveraging aggregated inspectional intelligence, we will analyze key regulatory “hot spots” for CGT/ATMP manufacturing and map them to the broader challenges of consistency and scalability. Case examples will demonstrate how data-driven benchmarking can identify vulnerabilities before they are flagged by inspectors, enabling organizations to shift from a reactive to a proactive compliance.

Attendees will leave with a forward-looking compliance strategy, combining regulatory foresight with tactical GMP actions to support robust, scalable, and review-ready CGT/ATMP manufacturing. Ultimately, the goal is to help the field sustain innovation without compromising compliance, ensuring that patients receive safe, effective therapies at the speed modern science makes possible.